Negotiating competing discourses: The decision to take menopausal hormone therapy following surgical menopause

Women and Health

Volumn 50, Issue 6, 2010, Pages 527-543

  Beverley, Burrell ^a   Valledor, Vivienne ^a   Crowe, Marie ^a   Whitehead, Lisa ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Medical; Menopausal hormone therapy; Menopause; Public health; Surgical menopause

Indexed keywords

AGED; ARTICLE; DECISION MAKING; EARLY MENOPAUSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INTERPERSONAL COMMUNICATION; INTERVIEW; MIDDLE AGED; NEW ZEALAND; OVARIECTOMY; QUALITATIVE RESEARCH; WOMEN'S HEALTH;

AGED; DECISION MAKING; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; INTERVIEWS AS TOPIC; MENOPAUSE, PREMATURE; MIDDLE AGED; NEGOTIATING; NEW ZEALAND; OVARIECTOMY; QUALITATIVE RESEARCH; WOMEN'S HEALTH;

EID: 78049343629     PISSN: 03630242     EISSN: 15410331     Source Type: Journal    
DOI: 10.1080/03630242.2010.516699     Document Type: Article

References (52)

1. Banks, E., and K. Canfell. 2009. Invited commentary: Hormone therapy risks and benefits-The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 170:24-28.
2. Barrett-Connor, E. 2002. Hormones and the health of women: Past, present, and future. Keynote address. Menopause 9:23-31.
3. Boorse, C. 1977. Health as a theoretical concept. Philos Sci 44:542-73.
4. Buist, D. S. M., K. M. Newton, D. L. Miglioretti, K. Beverly, M. T. Connelly, S. Andrade, et al. 2004. Hormone therapy prescribing patterns in the United States. Obstet Gynaecol 104:1042-1050.
5. Burrell, B. A. 2009. The replacement of the replacement in menopause: Hormone therapy, controversies, truth, and risk. Nurs Inquiry 16:212-22.
6. Crawford, R. 2004. Risk ritual and the management of control and anxiety in medical culture. Health: Interdisc J Soc Study Health, Illness & Med 8:505-528.
7. Dennerstein, L. 1996. Well-being, symptoms and the menopausal transition. Maturitas 23:147-157.
8. Ettinger, B., D. Grady, A. Tosteson, A. Pressman, and J. Macer. 2003. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. The American College of Obstetricians and Gynecologists 102(6):1225-1232.
9. FDA. 2004. FDA updates hormone therapy information for post menopausal women. Retrieved May 20, 2010, from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108243.htm
10. Foidart, J. M., J. Desreux, A. Pintiaux, and A. Gompel. 2007. Hormone therapy and breast cancer risk. Climacteric 10:54-61.
11. Foucault, M. 1972/1980. Power/knowledge: Selected interviews and other writings 1972-77, ed. C. Gordon. Translated by C. Gordon, L. Marshall, J. Mepham, and K. Soper. Brighton, U.K.: Harvester Press.
12. Foucault, M. 1977. Discipline and punish: The birth of the prison. London: Penguin.
13. Foucault, M. 1988. Technologies of the self. In Technologies of the self: A seminar with Michel Foucault, eds. M. L. Gutman and P. Hutton. Amherst, MA: University of Massachusetts.
14. Foucault, M. 1998. On the archaeology of the sciences: Response to the epistemological circle. In Aesthetics, method, and epistemology, ed. J. Faubion, pp. 297-333. New York: The New Press.
15. Galvin, R. 2002. Disturbing notions of chronic illness and individual responsibility: Towards a genealogy of morals. Health: Interdisc J Soc Study Health, Illness & Med 6:107-137.
16. Grady, D., D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, and M. Hlatky. 2002. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow up (HERS11). J Am Med Assoc 288:49-57.
17. Hammond, C. 2005. The Women's Health Initiative Study: Perspectives and implications for clinical practice. Rev Endocr & Metabol Disord 6:93-99.
18. Hendrix, S. 2005. Bilateral oopherectomy and premature menopause. Am J Med 118:131S-135S.
19. Hersh, A. L., M. Stefanick, and R. Stafford. 2004. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. J Am Med Assoc 291:47-53.
20. Hickey, M., S. Davis, and D. Sturdee. 2005. Treatment of menopausal symptoms; What shall we do now? Lancet 366:409-421.
21. Hoffmann, M., L. Lindh-Astrand, J. Ahlner, M. Hammar, & K. Kjellgren. 2005. Hormone replacement therapy in the menopause. Structure and content of risk talk. Maturitas 50:8-18.
22. Hulley, S., C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, et al. 2002. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow up (HERS11). J Am Med Assoc 288:58-64.
23. Hulley, S., D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff. 1998. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 280:605-613.
24. Institute for Quality and Efficiency in Health Care Germany. 2006, 2007. Decision aid: Hormone therapy for menopause. Retrieved from informedhealthonline.org Institute for Quality and Efficiency in Health Care Germany. 2007. Menopause. Retrieved December 7, 2007, from http://www.informedhealthonline.org/index.161.en.html
25. Krieger, N., I. Lowy, R. Aronowitz, J. Bigby, K. Dickersin, E. Garner, et al. 2005. Hormone replacement therapy, cancer, controversies, and women's health: Histori- cal, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol & Commun Health 59:740-748.
26. Majumdar, S., A. Almasi, and R. Stafford. 2004. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. J Am Med Assoc 292:1983-8.
27. McCrea, F. B. 1983. The politics of menopause: The discovery of a deficiency disease. Soc Problems 31:111-23.
28. National Heart, Lung, and Blood Institute. 2005. Facts about menopausal hormone therapy, 2nd Ed., original 2002. Retrieved December 4, 2007, from http://www. nhlbi.nih.gov/health/public/heart/other/pht_fact.htm
29. National Institutes of Health. 2005. State-of-the-Science Conference Statement: Man- agement of menopause-related symptoms. Ann Int Med 142:1003-1013.
30. National Institutes of Health. 2007. Menopausal hormone replacement therapy use and cancer: Questions and answers. Fact Sheet. Retrieved October 5, 2007, from http://www.cancer.gov/cancertopics/factsheet/Risk/menopausal-hormones.
31. Nedrow, A., J. Miller, M. Walker, P. Nygren, L. H. Huffman, and H. D. Nelson. 2006. Complementary and alternative therapies for the management of menopause- related symptoms: A systematic evidence review. Arch Int Med 166:1453-1465.
32. New Zealand Guidelines Group. 2004/2007. Hormone replacement therapy. Evidence based best practice guideline summary update. Retrieved December 4, 2007, from http://www.nzgg.org.nz/guidelines/0078/HRT_summary_web.pdf.
33. Office of Women's Health. 2004. Menopause campaign. OWH Update. Retrieved October 5, 2007, from http://www.fda.gov/womens/owhupdate/dec2004.html.
34. Palmlund, I. 2006. Loyalties in clinical research on drugs: The case of hormone replacement therapy. Soc Sci & Med 63:540-551.
35. Petitti, D. B. 2002. Hormone replacement therapy for prevention. More evidence, more pessimism. J Am Med Assoc 288:99-101.
36. Practice Committee of the American Society for Reproductive Medicine. 2008. Estrogen and progestogen therapy in postmenopausal women. Fertil & Steril 90:S88-S102.
37. Prentice, R., R. Langer, G. Anderson, and D. Barad. 2005. Prentice et al. respond to "How far can epidemiologists get with statistical adjustment?" Am J Epidemiol 162:419-420.
38. Rees, M. 2006. Gynecological oncological perspective on management of the menopause. J Cancer Surg 32:892-7.
39. Rock, J., and H. Jones, eds. 2008. Te Linde's Operative Gynecology, 10th ed. Philadelphia: Lippincott Williams & Wilkins.
40. Rose, N. 2006. Disorders without borders? The expanding scope of psychiatric practice. Biosocieties 1:465-84.
41. Sackett, D. 2002. The arrogance of preventative medicine. Can Med Assoc J 167: 363-364.
42. Scott, J. 1988. Deconstructing equality versus difference: Or, the uses of post structural theory for feminism. Feminist Stud 14:33-50.
43. Shuster, L. T., B. S. Gostout, B. R. Grossardt, and W. A. Rocca. 2008. Prophylactic oopherectomy in premenopausal women and long-term health. Menopause Int 14:111-116.
44. Statistics New Zealand. 2006. Census of population and dwellings 2006. Statistics New Zealand: Government Printer.
45. Stefanick, M. 2005. Estrogens and progestins: Background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 118:64-73.
46. Stephenson, J. 2003. FDA orders estrogen safety warnings: Agency offers guidance for HRT use. J Am Med Assoc 289:537-538.
47. Tiles, M. 1993. The normal and pathological: The concept of a scientific medicine. Br J Philos Sci 44:729-742.
48. Turner, B. 1992. Regulating bodies: Essays in medical sociology. London: Routledge.
49. Turner, B. 1997. Foreword: From governmentality to risk, some reflections on Fou- cault's contribution to medical sociology. In Foucault, Health and Medicine, eds. A. Petersen and R. Bunton. London: Routledge.
50. Utian, W. 1999. An historical perspective on natural and surgical menopause. Meno- pause 6:83-86.
51. Weedon, C. 1987. Feminist practice and poststructural theory. Oxford: Basil Black- well.
52. Writing Group for the Women's Health Initiative Investigators. 2002. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomised controlled trial. J Am Med Assoc 288:321-333.